[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586967":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":17,"locations":10,"responsibleParty":23,"collaborators":26,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":33,"acronym":34,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":10,"enrollmentInfo":38,"targetDuration":41,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":10},{"fullName":5,"class":6},"Ospedale San Raffaele","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Non-small cell lung cancer (NSCLC) patients",null,"Adult subjects with diagnosis of non-small cell lung cancer (NSLC) that could undergo surgery or neo-adjuvant treatment.",[13],{"name":14,"affiliation":15,"role":16},"Chiara M Cattaneo, PhD","IRCCS Ospedale San Raffaele","PRINCIPAL_INVESTIGATOR",[18],{"name":14,"role":19,"phone":20,"phoneExt":21,"email":22},"CONTACT","+39022643","4712","cattaneo.chiara@hsr.it",{"type":16,"investigatorFullName":24,"investigatorTitle":25,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chiara Maria Cattaneo","PhD",[27],{"name":28,"class":6},"Fondazione Umberto Veronesi","100586967","personalizing-adoptive-cell-transfer-for-solid-tumors-towards-a-new-patient-tailored-treatment-option-100586967",false,"NCT06922266","Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option","Chewbacca","Inclusion Criteria:\n\n* Participant is willing and able to provide informed consent for participation in the study.\n* Age: Adults aged 18 years or older.\n* Diagnosis: non-small cell lung cancer (Stage I-II, III), with or without lymph node involvement, ideally with sufficient tumor burden to provide adequate tissue for analysis. In accordance with good clinical practice, patients with early-stage disease will undergo direct surgery, whereas patients with advanced-stage disease will receive neoadjuvant treatment followed by surgery.\n* Ability to attend scheduled follow-up visits, if applicable, for additional peripheral blood sample collection during treatment.\n\nExclusion Criteria:\n\n* Presence of any active infection or underlying condition that could compromise the safety of tissue and blood sampling.\n* Prior history of another malignancy that might interfere with data interpretation related to non-small cell lung cancer progression and immune response.\n* Any current use of immunosuppressive medications (e.g., high-dose steroids) which might alter immune response assessments, except as part of non-small cell lung cancer treatment.\n* Pregnancy and breastfeeding","ALL","18 Years",{"count":39,"type":40},20,"ESTIMATED","4 Years","OBSERVATIONAL","This is a monocentric prospective observational study. This study will include patients with a diagnosis of non-small cell lung cancer for the collection of blood and tissue specimens.",[45],"Carcinoma, Non-Small-Cell Lung",[47,48,49,50],"Immunotherapy","Precision Oncology","Lung cancer","Adoptive Cell Transfer","NOT_YET_RECRUITING","2025-04-03",{"date":54,"type":55},"2025-04-10","ACTUAL",{"date":57,"type":40},"2025-05-01",{"date":59,"type":40},"2029-04-30",{"name":5,"class":6}]